BAUSCH + LOMB HIGHLIGHTS SURGICAL, PHARMACEUTICAL AND CONSUMER HEALTH CARE INNOVATIONS AND NEW BUSINESS VENTURES; OFFERS EDUCATIONAL OPPORTUNITIES DURING THE ANNUAL MEETING OF THE AMERICAN ACADEMY OF OPHTHALMOLOGY
New SimplifEYE™ Intraocular Lens Delivery System among Technologies Featured at Virtual Booth Prominent Surgeons to Host Industry Showcase Presentations
BRIDGEWATER, N.J., Nov. 10, 2020 –
“We are proud of the progress that we have made this year, and the resolve that the entire eye care community has demonstrated, despite the many challenges that we’ve encountered,” said Joe Gordon, U.S. president,
Innovations Featured in Booth
Launched in October, the SimplifEYE™ intraocular lens (IOL) delivery system is exclusively available for the enVista® MX60PL and the enVista® toric MX60PT, the first preloaded toric IOL available in the United States. This new system facilitates smooth and consistent implantation of enVista lenses in just three steps through an incision as small as 2.2mm.
New additions to our extensive retina portfolio include the 27-gauge endoilluminator is 156% more rigid and 20% brighter than the previous 25-gauge design. These improvements allow the user to confidently manipulate the endoilluminator while facilitating improved access and visualization of the periphery during retina surgery.
Attendees are invited to visit the
The company’s proprietary Pharmaceutical products will also be featured in the booth. These include BEPREVE® (bepotastine besilate ophthalmic solution) 1.5%, BESIVANCE® (besifloxacin ophthalmic suspension) 0.6%, LOTEMAX® SM (loteprednol etabonate ophthalmic gel) 0.38%, ISTALOL® (timolol maleate ophthalmic solution) 0.5%, LACRISERT® (hydroxypropyl cellulose ophthalmic insert), RETISERT® (fluocinolone acetonide intravitreal implant) 0.59 mg, PROLENSA® (bromfenac ophthalmic solution) 0.07% and VYZULTA® (latanoprostene bunod ophthalmic solution) 0.024%.
PreserVision® AREDS 2 Formula eye vitamins, which are from the company's Consumer Health Care division, will also be highlighted in the booth. PreserVision® is the most studied eye vitamin brand based on the AREDS and AREDS2 clinical studies conducted by the National Eye Institute (NEI). These vitamins contain the exact nutrient formula recommended by the NEI to help reduce the risk of moderate to advanced Age-related Macular Degeneration (AMD) progression.*
For details about enVista lenses, indications and important safety information, please click here.
Business Development News
Earlier this year,
The company also recently received an exclusive license to Eyenovia’s investigational microdose formulation of atropine ophthalmic solution, which is being investigated for the reduction of pediatric myopia progression in children ages 3-12. This investigational formulation of atropine is delivered with Eyenovia's Optejet dispenser technology and, if approved, would be another important step forward in the company’s progress to finding treatments to meet the needs of myopia patients.
Industry Showcase Presentations
Virtual Industry Showcase presentations hosted by
Friday, Nov. 13:
- “Expert Post-Operative Case Management During Uncertain Times” presented by Paul Singh, M.D., at 8:45 a.m. PT (session #: ISC02).
- “Clinical Glaucoma Management During the COVID-19 Pandemic” presented by Shan Lin, M.D., at 2:40 p.m. PT
(session #: ISC08).
Saturday, Nov. 14:
- “Bi-Blade® Dual-Port Technology: Advancing Efficiency & Stability in Vitreoretinal Surgery” presented by Sunir Garg, M.D., and Rahul Reddy, M.D., at 6 a.m. PT (session #: ISC13).
- “Astigmatism Correction with enVista® Toric: SimplifEYE’d” presented by Mitchell Shultz, M.D., and Marjan Farid, M.D., at 1 a.m. PT (session #: ISC20).
Sunday, Nov. 15:
- “Can Your Femto Do This? A Focus on VICTUS® Corneal Work” presented by Michael J. Endl, M.D., and Thomas R. Elmer, Jr., M.D., at 6 a.m. PT (session #: ISC65).
- “Understanding Phacodynamics: Misconceptions vs. Facts” presented by Barry S. Siebel, M.D., and Timothy P. Page, M.D., at 2:05 p.m. PT (session #: ISC35).
This news release may contain forward-looking statements, which may generally be identified by the use of the words “anticipates,” “expects,” “intends,” “plans,” “should,” “could,” “would,” “may,” “believes,” “estimates,” “potential,” “target,” or “continue” and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health’s most recent annual report on Form 10-K and detailed from time to time in Bausch Health’s other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving COVID-19 pandemic, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on Bausch Health, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Bausch Health undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law.
®/TM are trademarks of Bausch & Lomb Incorporated or its affiliates.
Any other product/brand names are trademarks of the respective owners.
© 2020 Bausch & Lomb Incorporated or its affiliates. MTB.0382.USA.20